Laboratory Developed Tests Market (2026-2036)

The growth of this market is mainly driven by the ability of laboratories to bring tests into clinical use far more quickly than the commercial approval pathway allows, which makes laboratory developed tests the route by which most novel molecular, genomic, and biomarker testing reaches patients; the rapid expansion of precision oncology, molecular residual disease monitoring, and multi-cancer early detection; the absence of commercially approved equivalents for rare diseases and for many emerging biomarkers; and the resolution of regulatory uncertainty in the U.S. following the vacatur of the FDA final rule. In addition, the growth of blood-based screening, the expansion of pharmacogenomic and reproductive testing, the integration of artificial intelligence (AI) with laboratory testing, and the growth of specialty and academic laboratory capacity in Asia-Pacific and Europe are further supporting the growth of this market.

The Laboratory Developed Tests Market, also referred to as the LDT market, in-house diagnostic test market, or clinical laboratory in-house assay market, comprises the clinical testing services performed using assays that a laboratory designs, validates, manufactures, and uses within its own facility, rather than purchasing an approved test kit from a diagnostic manufacturer. The market covers testing revenue earned from these assays across molecular and genomic methods, including polymerase chain reaction (PCR), next-generation sequencing (NGS), and digital PCR; immunoassay and protein-based methods; mass spectrometry; flow cytometry and cytogenetics; and multi-analyte algorithmic assays that combine measured markers with computational interpretation. The market ecosystem extends from academic medical centre laboratories, national reference laboratories, and specialty commercial laboratories to hospitals and health systems, physicians and oncologists who order the tests, payers who reimburse them, pharmaceutical companies that use them in trials and companion testing, and the accreditation bodies and regulators that oversee them.

Laboratory developed tests exist because the pace of clinical science exceeds the pace of commercial test approval. When a new biomarker, gene, or variant becomes clinically actionable, a laboratory with the necessary expertise can design and validate an assay for it within months, whereas a manufacturer must develop a kit, run clinical studies, and obtain regulatory clearance over a far longer period, and will only do so where the market is large enough to justify the investment. The consequence is that most novel molecular and genomic testing, and almost all testing for rare conditions, reaches patients as a laboratory developed test. This is a structural feature of diagnostics rather than a transitional one.

The regulatory position in the U.S. has resolved in a way that supports the model. In the U.S., the Food and Drug Administration (FDA) final rule of May 2024, which would have phased laboratory developed tests into device regulation, was vacated by the U.S. District Court for the Eastern District of Texas in March 2025, no appeal was filed, and in August 2025 the FDA signaled its intention to rescind the rule, leaving laboratory developed tests to be regulated primarily under Clinical Laboratory Improvement Amendments (CLIA) requirements and laboratory accreditation programs. The College of American Pathologists has aligned its Laboratory Accreditation Program checklists with revised CLIA requirements that took effect in December 2024, including changes to laboratory director and testing personnel qualifications and extended eligibility for individualized quality control plans, reflecting the accreditation framework under which laboratory developed tests are validated and monitored. Laboratories must validate each assay, establish and monitor performance specifications, operate documented quality control, participate in proficiency testing, and demonstrate all of this during inspection. Responsibility for analytical and clinical validity therefore rests with the laboratory, which is a substantial obligation, but one that laboratories are equipped to discharge and that does not require the time and cost of premarket review.

Precision oncology is the largest and most dynamic application. Comprehensive genomic profiling, molecular residual disease monitoring, and therapy selection testing are performed predominantly as laboratory developed tests, because gene content, variant interpretation, and reporting must be updated continuously as evidence changes. In the second quarter of 2026, Natera, Inc. reported revenue of USD 752.8 million, up 37.7% year over year, processed approximately 1,043,900 tests, up 22.4%, including approximately 296,700 oncology tests, up 57.2%, and raised its full-year 2026 revenue guidance by USD 100 million at the midpoint to USD 2.85-2.91 billion. In the second quarter of 2026, Tempus AI, Inc. reported revenue of USD 382.5 million, up 22% year over year, with oncology testing volume up 31%, 9,000 molecular residual disease tests, and Data and Applications revenue of USD 93.2 million, up 28%. The growth rates these laboratories report substantially exceed those of the wider clinical laboratory market.

Blood-based screening represents the newest and potentially largest opportunity. In the second quarter of 2026, Guardant Health, Inc. reported revenue of USD 335.0 million, up 44% year over year, with oncology revenue of USD 219.1 million on approximately 104,000 tests, up 63%, and screening revenue of USD 52.9 million on approximately 66,000 Shield tests, compared with approximately 16,000 a year earlier, and raised its full-year 2026 revenue guidance to USD 1.34-1.36 billion. A screening test addresses an eligible population measured in tens of millions rather than the much smaller populations eligible for diagnostic or monitoring tests, and the volume trajectory of early screening offerings indicates how rapidly adoption can proceed once reimbursement and guideline support are in place.

Established reference laboratories participate alongside the specialists. In the second quarter of 2026, Quest Diagnostics Incorporated reported revenue of USD 3.04 billion, up 10.2% year over year, with requisition volume up 13.1%, double-digit revenue growth in several advanced diagnostics areas including its Alzheimer blood test and advanced cardiometabolic testing, New York State approval of its Haystack molecular residual disease test, and raised full-year 2026 revenue guidance of USD 11.95-12.05 billion. Quest Diagnostics and Labcorp operate extensive menus of in-house assays alongside approved kits, and have expanded into molecular residual disease, neurology, and advanced cardiometabolic testing, in several cases through acquisition of specialty capability. Academic medical centre laboratories and national reference laboratories such as ARUP and Mayo Clinic Laboratories remain the principal source of testing for rare and ultra-rare conditions.

Reimbursement, rather than regulation, is now the principal commercial constraint. In the second quarter of 2026, Myriad Genetics, Inc. reported revenue of USD 190.7 million, down 11% year over year, with hereditary cancer testing volume up 8% but hereditary cancer revenue down 13% on lower reimbursement and unfavorable estimate changes, and lowered its full-year 2026 revenue guidance to USD 770-790 million while suspending adjusted EBITDA guidance. The contrast between laboratories reporting rapid growth and those reporting revenue declines despite rising volumes illustrates that coverage decisions, coding, and payment rates determine commercial outcomes more directly than scientific merit or test volume. Laboratories consequently invest heavily in evidence generation, guideline inclusion, and payer engagement.

The market includes specialty molecular laboratories such as Natera, Guardant Health, Exact Sciences, Tempus AI, Myriad Genetics, NeoGenomics, and Fulgent Genetics; national reference laboratories including Quest Diagnostics and Labcorp; Foundation Medicine within Roche; and academic and non-profit reference laboratories including ARUP Laboratories and Mayo Clinic Laboratories. These organizations compete on clinical validity and published evidence, guideline inclusion, reimbursement coverage, turnaround time, menu breadth, physician and health system relationships, interpretive reporting, and the integration of testing with clinical and data platforms.

At the same time, the market faces challenges, including reimbursement uncertainty and the cost of generating the evidence coverage requires, the possibility that legislative proposals will revive a federal oversight framework, variation in test performance and interpretation between laboratories offering nominally similar assays, pricing pressure on established test categories, shortages of clinical laboratory and genetic counselling personnel, and the cost of validating and maintaining large and frequently updated test menus. As a result, laboratories that combine demonstrated clinical utility, secured reimbursement, efficient operations at scale, and defensible interpretive capability are expected to capture the largest share of growth over the forecast period.